Business Description
Anixa Biosciences Inc
NAICS : 541713
SIC : 2834
ISIN : US45069V2034
Total Employee Number:
4Description
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 74.38 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 7.6 | |||||
3-Year EPS without NRI Growth Rate | 8.9 | |||||
3-Year FCF Growth Rate | -1.1 | |||||
3-Year Book Growth Rate | -21.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -4.13 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.95 | |||||
9-Day RSI | 56.82 | |||||
14-Day RSI | 57.51 | |||||
3-1 Month Momentum % | -11.55 | |||||
6-1 Month Momentum % | -23.73 | |||||
12-1 Month Momentum % | -18.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.79 | |||||
Quick Ratio | 9.79 | |||||
Cash Ratio | 9.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | -4.58 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -64.84 | |||||
ROA % | -62.09 | |||||
ROIC % | -4581.55 | |||||
3-Year ROIIC % | -9058.33 | |||||
ROC (Joel Greenblatt) % | -5548.34 | |||||
ROCE % | -73.98 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.17 | |||||
Price-to-Tangible-Book | 7.04 | |||||
EV-to-EBIT | -8.37 | |||||
EV-to-Forward-EBIT | -6.36 | |||||
EV-to-EBITDA | -8.4 | |||||
EV-to-FCF | -12.56 | |||||
| Price-to-Net-Current-Asset-Value | 7.23 | |||||
| Price-to-Net-Cash | 7.87 | |||||
Earnings Yield (Greenblatt) % | -11.95 | |||||
FCF Yield % | -6.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anixa Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.265 | ||
| Beta | 1.2887 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.23 | ||
| Volatility % | 51.19 | ||
| 14-Day RSI | 57.51 | ||
| 14-Day ATR (€) | 0.173446 | ||
| 20-Day SMA (€) | 2.523 | ||
| 12-1 Month Momentum % | -18.41 | ||
| 52-Week Range (€) | 1.998 - 4.8 | ||
| Shares Outstanding (Mil) | 34.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anixa Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anixa Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-01-12 | In 181 days | ||
| Second quarter earnings results for 2026 | 2026-06-10 | 2.06 (-1.91%) | ||
| RedChip Biotech Resurgence: Platforms and Pipelines of Today\'s Innovators virtual investor conference | 2026-04-16 15:30 | 2.42 (+1.68%) | ||
| Water Tower Research Insights Conference | 2026-04-14 12:30 | 2.38 (+6.73%) | ||
| General meeting for 2026 | 2026-03-10 10:00 | 2.50 (+5.04%) | ||
| First quarter earnings results for 2026 | 2026-03-09 | 2.42 (-0.82%) | ||
| Annual report for 2025 | 2026-01-12 | 2.88 (+0.00%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-09 10:30 | 2.48 (+1.64%) | ||
| Second quarter earnings results for 2025 | 2025-05-28 | 2.14 (+0.94%) | ||
| H.C. Wainwright 3rd Annual BioConnect Investor Conference | 2025-05-20 11:00 | 2.34 (+2.63%) |
Show
Entries
Anixa Biosciences Inc Frequently Asked Questions
What is Anixa Biosciences Inc(STU:CY71)'s stock price today?
The current price of STU:CY71 is €2.68. The 52 week high of STU:CY71 is €4.80 and 52 week low is €2.00.
When is next earnings date of Anixa Biosciences Inc(STU:CY71)?
The next earnings date of Anixa Biosciences Inc(STU:CY71) is 2026-09-10 Est..
Does Anixa Biosciences Inc(STU:CY71) pay dividends? If so, how much?
Anixa Biosciences Inc(STU:CY71) does not pay dividend.
Press Release
Articles on Anixa Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers